7 OVERVIEW

7 Latest key takeaways

9 DISEASE BACKGROUND

9 Migraine without aura

9 Migraine with aura

10 TREATMENT

10 Analgesics

10 NSAIDs

10 Serotonergic drugs

11 CGRP inhibitors

11 Prophylactic agents for migraine

12 EPIDEMIOLOGY

12 Prevalence methodology

16 MARKETED DRUGS

22 PIPELINE DRUGS

31 KEY REGULATORY EVENTS

31 Cefaly Touts First OTC Dual-Purpose eTNS Migraine Device

31 Cipla Gets CGT Nod For US Migranal Rival

31 Biohaven Goes All In On ODT With Nurtec

32 Dr Reddy's Elyxyb Receives US Approval For Its NDA

32 FDA Issues Response Letter For Rizaport

32 Relief For Migraine as England's NICE Reverses Ajovy Knockback

32 Yes For Shionogi But No For Lilly In Latest EMA Recommendations

33 Biohaven's Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

33 Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

33 Triptan Switches Offer Hope For Australia's OTC Market

33 Allergan's Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks

34 Lilly Expands Migraine Franchise With Reyvow Approval

34 IntelGenx Takes A Fourth Try At Rizaport Approval

35 PROBABILITY OF SUCCESS

36 LICENSING AND ASSET ACQUISITION DEALS

36 Biohaven secures up to $450m deal with Royalty Pharma

36 Currax Gains NA License To Optinose's Onzetra Xsail Migraine Treatment

36 Deals Shaping The Medical Industry, October 2019

37 CLINICAL TRIAL LANDSCAPE

38 Sponsors by status

39 Sponsors by phase

40 Recent events

42 DRUG ASSESSMENT MODEL

42 Acute migraine

43 Chronic and episodic migraine prevention

46 MARKET DYNAMICS

48 FUTURE TRENDS

48 Brand awareness among HCPs will contribute to growth

48 Oral CGRPs for migraine prophylaxis have the greatest commercial potential

50 CONSENSUS FORECASTS

52 RECENT EVENTS AND ANALYST OPINION

52 Qtrypta for Migraine (October 21, 2020)

52 Qtrypta for Migraine (September 30, 2020)

53 Reyvow for Migraine (September 11, 2020)

55 STS101 for Migraine (September 10, 2020)

57 Atogepant for Migraine (July 29, 2020)

59 INP-104 for Migraine (June 10, 2020)

61 AXS-07 for Migraine (April 6, 2020)

63 Nurtec ODT for Migraine (March 30, 2020)

65 AXS-07 for Migraine (December 30, 2019)

67 Zavegepant for Migraine (December 17, 2019)

69 KEY UPCOMING EVENTS

70 UNMET NEEDS

71 BIBLIOGRAPHY

71 Prescription information

73 APPENDIX

LIST OF FIGURES

14 Figure 1: Trends in prevalent cases of migraine, 2019-28

22 Figure 2: Overview of pipeline drugs for migraine in the US

23 Figure 3: Pipeline drugs for migraine, by company

23 Figure 4: Pipeline drugs for migraine, by drug type

23 Figure 5: Pipeline drugs for migraine, by classification

35 Figure 6: Probability of success in the migraine pipeline

37 Figure 7: Clinical trials in migraine

37 Figure 8: Top 10 drugs for clinical trials in migraine

38 Figure 9: Top 10 companies for clinical trials in migraine

38 Figure 10: Trial locations in migraine

39 Figure 11: Migraine trials status

40 Figure 12: Migraine trials sponsors, by phase

42 Figure 13: Datamonitor Healthcare's drug assessment summary for migraine

46 Figure 14: Market dynamics in migraine (1 of 2)

47 Figure 15: Market dynamics in migraine (2 of 2)

48 Figure 16: Future trends in migraine

55 Figure 17: Reyvow for Migraine (September 11, 2020): Phase III - CENTURION (>4 Migraine Attacks)

57 Figure 18: STS101 for Migraine (September 10, 2020): Phase III - EMERGE

59 Figure 19: Atogepant for Migraine (July 29, 2020): Phase III - ADVANCE

61 Figure 20: INP-104 for Migraine (June 10, 2020): Phase III - STOP-301

63 Figure 21: AXS-07 for Migraine (April 6, 2020): Phase III - INTERCEPT (Early)

65 Figure 22: Nurtec ODT for Migraine (March 30, 2020): Phase II/III - BHV3000-305 (Migraine Prevention)

67 Figure 23: AXS-07 for Migraine (December 30, 2019): Phase III - MOMENTUM (Acute)

68 Figure 24: Zavegepant for Migraine (December 17, 2019): Phase II/III - 201

69 Figure 25: Key upcoming events in migraine

LIST OF TABLES

13 Table 1: Prevalent cases of migraine, 2019-28

15 Table 2: Prevalence proportions of migraine, 2019-28

17 Table 3: Marketed drugs for migraine

25 Table 4: Pipeline drugs for migraine in the US

50 Table 5: Historical global sales, by drug ($m), 2015-19

51 Table 6: Forecasted global sales, by drug ($m), 2020-24

52 Table 7: Qtrypta for Migraine (October 21, 2020)

53 Table 8: Qtrypta for Migraine (September 30, 2020)

54 Table 9: Reyvow for Migraine (September 11, 2020)

56 Table 10: STS101 for Migraine (September 10, 2020)

58 Table 11: Atogepant for Migraine (July 29, 2020)

60 Table 12: INP-104 for Migraine (June 10, 2020)

62 Table 13: AXS-07 for Migraine (April 6, 2020)

64 Table 14: Nurtec ODT for Migraine (March 30, 2020)

65 Table 15: AXS-07 for Migraine (December 30, 2019)
67 Table 16: Zavegepant for Migraine (December 17, 2019)